Eli Lilly And Co (NYSE:LLY) Price Target Increased to $164.00 by Analysts at Mizuho
Eli Lilly And Co (NYSE:LLY) had its price objective lifted by stock analysts at Mizuho from $155.00 to $164.00 in a research report issued on Monday, The Fly reports. The firm currently has a “neutral” rating on the stock. Mizuho’s target price would suggest a potential downside of 0.11% from the stock’s previous close.
A number of other equities analysts have also commented on LLY. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Bank of America restated a “buy” rating and issued a $180.00 price objective on shares of Eli Lilly And Co in a research report on Friday, June 19th. Morgan Stanley lowered shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research report on Sunday, April 19th. Cfra lifted their target price on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Guggenheim upgraded shares of Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 target price for the company in a research report on Tuesday, June 16th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $168.58.
LLY stock opened at $164.18 on Monday. The firm has a 50 day moving average of $154.33 and a 200-day moving average of $143.38. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $167.43. The firm has a market capitalization of $155.63 billion, a P/E ratio of 27.14, a price-to-earnings-growth ratio of 1.51 and a beta of 0.24.
In related news, major shareholder Lilly Endowment Inc sold 11,431 shares of Eli Lilly And Co stock in a transaction on Monday, June 29th. The shares were sold at an average price of $163.39, for a total value of $1,867,711.09. Following the transaction, the insider now directly owns 111,727,744 shares of the company’s stock, valued at $18,255,196,092.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Aarti S. Shah sold 2,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the transaction, the senior vice president now directly owns 19,087 shares in the company, valued at $2,863,050. The disclosure for this sale can be found here. Insiders have sold 982,938 shares of company stock worth $151,390,042 over the last three months. Insiders own 0.09% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Stonebridge Financial Planning Group LLC increased its stake in shares of Eli Lilly And Co by 70.0% in the first quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock worth $25,000 after buying an additional 70 shares during the period. Pacitti Group Inc. purchased a new position in shares of Eli Lilly And Co in the fourth quarter worth $25,000. Truvestments Capital LLC purchased a new position in shares of Eli Lilly And Co in the first quarter worth $27,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Eli Lilly And Co during the 1st quarter valued at $34,000. Finally, Bainco International Investors purchased a new position in Eli Lilly And Co during the 1st quarter valued at $34,000. 77.44% of the stock is currently owned by institutional investors.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Municipal Bonds
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.